-
Mashup Score: 19
Acute toxicity following prostate radiotherapy was statistically significantly associated with late toxicity and with decrement in patient-reported QOL metrics. These data support efforts to evaluate whether interventions that reduce acute toxicity ultimately reduce the risk of late toxicity.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 25
JCO PO author Dr. Amar U. Kishan, Professor, Executive Vice Chair, and Chief of Genitourinary Oncology Service in the Department of Radiation Oncology at the University of California, Los Angeles, shares insights into his JCO PO article, “Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study.” Host Dr. Rafeh Naqash and Dr. Kishan discuss the relationship between Decipher genomic classifier scores and prostate-specific membrane antigen (PSMA) PET/CT-based metastatic spread.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Happy to join the JCO Precision Oncology Conversations podcast https://t.co/hlh7YjfpWG to discuss our recent publication https://t.co/g1NPF8IJS5. @JCOPO_ASCO @thenasheffect
-
-
Mashup Score: 25
JCO PO author Dr. Amar U. Kishan, Professor, Executive Vice Chair, and Chief of Genitourinary Oncology Service in the Department of Radiation Oncology at the University of California, Los Angeles, shares insights into his JCO PO article, “Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study.” Host Dr. Rafeh Naqash and Dr. Kishan discuss the relationship between Decipher genomic classifier scores and prostate-specific membrane antigen (PSMA) PET/CT-based metastatic spread.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Happy to join the JCO Precision Oncology Conversations podcast https://t.co/hlh7YjfpWG to discuss our recent publication https://t.co/g1NPF8IJS5. @JCOPO_ASCO @thenasheffect
-
-
Mashup Score: 110Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial - 4 month(s) ago
Image-guided adaptive radiotherapy allowed bladder tumour radiotherapy dose escalation without a significant increase in toxicity. The use of multiple adaptive plans suggests an on-going need for radiotherapy optimisation with adaptive therapy. Dose escalation achieves promising tumour control with low salvage cystectomy rates.
Source: www.europeanurology.comCategories: General Medicine News, Hem/OncsTweet-
RAIDER trial out in @EUplatinum https://t.co/jTF4TZhP5A Congrats to @robert_huddart @EmmaHall71 @achoud72 on this large trial of bladder preservation with innovative exploration of adaptive therapy. Extremely low rates of grade 3 toxicity and salvage cystectomy
-
-
Mashup Score: 108Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial - 4 month(s) ago
Image-guided adaptive radiotherapy allowed bladder tumour radiotherapy dose escalation without a significant increase in toxicity. The use of multiple adaptive plans suggests an on-going need for radiotherapy optimisation with adaptive therapy. Dose escalation achieves promising tumour control with low salvage cystectomy rates.
Source: www.europeanurology.comCategories: General Medicine News, Hem/OncsTweet-
RAIDER trial out in @EUplatinum https://t.co/jTF4TZhP5A Congrats to @robert_huddart @EmmaHall71 @achoud72 on this large trial of bladder preservation with innovative exploration of adaptive therapy. Extremely low rates of grade 3 toxicity and salvage cystectomy
-
-
Mashup Score: 108Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial - 4 month(s) ago
Image-guided adaptive radiotherapy allowed bladder tumour radiotherapy dose escalation without a significant increase in toxicity. The use of multiple adaptive plans suggests an on-going need for radiotherapy optimisation with adaptive therapy. Dose escalation achieves promising tumour control with low salvage cystectomy rates.
Source: www.europeanurology.comCategories: General Medicine News, Hem/OncsTweet-
RAIDER trial out in @EUplatinum https://t.co/jTF4TZhP5A Congrats to @robert_huddart @EmmaHall71 @achoud72 on this large trial of bladder preservation with innovative exploration of adaptive therapy. Extremely low rates of grade 3 toxicity and salvage cystectomy
-
-
Mashup Score: 10Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer - 11 month(s) ago
We conducted a trial in which effective multimodal therapies without long-term castration were combined with the aim of achieving durable remission in patients with de novo oligometastatic prostate cancer. Here we report primary analysis results from SOLAR, a single-arm prospective phase 2 trial of primary tumor–directed therapy, metastasis-directed therapy (MDT) [1], and intensified systemic therapy of limited duration conducted within the Veterans Affairs health care system.
Source: www.europeanurology.comCategories: General Medicine News, Hem/OncsTweet-
@ChadTangMD A paired trial, also published in @EUplatinum , was Nick Nickol's SOLAR trial at the Greater LA VA: https://t.co/c8SyQ5vHM8
-
-
Mashup Score: 41When Headlines Harm Patients With Cancer - 1 year(s) ago
This Viewpoint discusses journalists’ responsibility to report study results objectively, without dramatic headlines, to avoid hindering patients’ decision-making about treatments.
Source: jamanetwork.comCategories: General Medicine News, Oncologists1Tweet-
Very insightful article from former @UCLAJCCC radonc resident Narek Shavedian @MSK_RadOnc and @reshmajagsi in @JAMAOnc on inaccurate headlines and impact on patients (specifically re: recent breast cancer and RT omission) https://t.co/lX8CvuerGd
-
-
Mashup Score: 20
Real-time intrafraction tracking/gating is an integral component of MRI-guided radiotherapy (MRgRT), and may have contributed to the acute toxicity reduction during prostate stereotactic body radiotherapy (SBRT) observed on the MRgRT-arm of the MIRAGE randomized trial (NCT04384770). Herein we characterized intrafraction prostate motion and assessed gating effectiveness.
Source: www.redjournal.orgCategories: General Medicine News, Hem/OncsTweet-
@weeloonong @DrSpratticus @SouMyajiT_RO @SeanMcGuireMD @DocJarad @MSteinbergMD The second is a post-hoc analysis of gating on the MIRAGE trial https://t.co/1yRib3aVX9. Here we see that a fair number of patients (30%) had at least one fraction in which 20% or more of the treatment time had the beam held due to motion.
-
-
Mashup Score: 46
A suboptimal prostate-specific antigen (PSA) response to neoadjuvant androgen deprivation therapy (ADT) among men who go on to receive definitive radiotherapy for prostate cancer might suggest the existence of castration-resistant disease or altered androgen receptor (AR) signaling. This in turn may portend worse long-term clinical outcomes, especially in men with high-risk disease. We set out to evaluate the prognostic impact of poor PSA response to neoadjuvant ADT in men with high-risk prostate cancer.
Source: www.redjournal.orgCategories: General Medicine News, Hem/OncsTweet-
Proud of my team @UCLAJCCC radiation oncology for having two papers in press @IJROBP right at the close of 2023! https://t.co/CIrVdCnXB4 https://t.co/1yRib3aVX9
-
Proud to share work led by John Nikitas PGY-5 @UCLAHealth out in @TheLancetOncol https://t.co/5p13rBLhPx We leveraged toxicity data from 6 trials in the MARCAP consortium to establish a clear link between acute toxicity and late toxicity following prostate radiotherapy